Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Reversing Tumor Immunotherapy Resistance via TME Modulation

Project description

T cell reactivation by targeting the tumour microenvironment

Tumours are surrounded by a complex ecosystem known as the tumour microenvironment (TME) that consists of immune cells, blood vessels, metabolites, and structural components. The TME affects tumour growth and treatment response, often by actively blocking T cell infiltration and suppressing their function, thereby limiting the success of immunotherapies. The ERC-funded REVIVE project builds on the discovery of a metabolite-activated receptor that weakens T cells within tumours. Blocking this receptor restores T cell infiltration, persistence, and killing capacity, markedly improving multiple immunotherapy approaches. The project is expected to optimise therapeutic antibodies against this receptor and validate their safety and efficacy. Moreover, researchers aim to develop biomarkers for patient selection and establish a clear path to clinical translation and commercialisation.

Objective

T cell infiltration and persistence in solid tumors are crucial for the success of T cell-based immunotherapies, yet the tumor microenvironment (TME) often suppresses T cell access and function. Our ERC-funded research has identified a G protein-coupled receptor (GPCR), activated by a metabolite commonly enriched in solid tumors, that substantially impairs T cells. We showed that inhibition of this GPCR enhances T cell infiltration, persistence, and cytotoxicity, thereby substantially improving the efficacy of CAR-T, TCR-T, and immune checkpoint blockade (ICB) therapies across tumor models of various cancer types.

To advance these findings towards clinical applications, we developed monoclonal antibodies (mAb) against this GPCR, which exhibit potent blocking functions and high specificity. Our lead mAb effectively reactivates patient-derived tumor-infiltrating lymphocytes (TILs) against autologous primary tumor cells, underscoring its therapeutic potential.

Project REVIVE aims to 1) humanize and optimize our mAbs target this GPCR, 2) conduct preclinical validation to assess efficacy and safety in advanced models, 3) develop predictive biomarkers for patient selection, and 4) establish a comprehensive intellectual property (IP) and commercialization strategy, integrating freedom to operate (FTO) analyses, market assessment, licensing opportunities, and industry partnerships to facilitate clinical translation.

By executing these steps, REVIVE will generate an investor-ready, clinically viable, IP-protected antibody targeting this GPCR, supported by comprehensive preclinical validation and a biomarker-driven patient selection strategy. These outcomes will enhance the commercial attractiveness of our therapeutic candidate for licensing or spin-out opportunities, paving the way for future clinical translation and patient benefit.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Net EU contribution
€ 150 000,00
Address
IM NEUENHEIMER FELD 280
69120 Heidelberg
Germany
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)